Seattle Genetics, Inc.

About Seattle Genetics, Inc.

Committed to improving patient outcomes
At Seattle Genetics, we are committed to developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and autoimmune diseases. We are dedicated to addressing unmet medical need, and strive to achieve that goal through an unwavering commitment to excellence in clinical development.

Focusing on Clinical Development
Seattle Genetics is a clinical stage biotechnology company advancing a broad product pipeline of antibody-based therapies. Our lead program, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the FDA for patients with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is empowered by Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. In addition, we are conducting clinical trials with four other product candidates, lintuzumab (SGN-33), dacetuzumab (SGN-40) and SGN-75, for the treatment of cancer, and SGN-70, for autoimmune diseases. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.

Our proprietary ADC technology empowers antibodies by stably linking them to cell-killing drug payloads. The drug payload is inactive until released from the antibody inside the targeted cancer cell, thereby sparing normal tissue the toxicity of traditional chemotherapy. In addition to brentuximab vedotin, SGN-75 is an ADC that is in a phase I clinical trial and we are developing several preclinical ADC product candidates, including ASG-5ME, which is advancing towards a planned 2010 clinical trial for solid tumors.

Expanding Our Opportunities Through Collaboration
Collaborating with leading biopharmaceutical companies is a cornerstone of Seattle Genetics' business strategy. Product-focused collaborations, such as our exclusive worldwide collaboration agreement with Genentech (a wholly owned member of the Roche Group) to develop and commercialize dacetuzumab, provide significant near- and mid-term funding while bringing in additional resources and expertise to support, advance and expand promising development programs. Collaboration and license agreements around our proprietary ADC technology also generate cash for the company - more than $75 million to date - while providing further clinical validation of the ADC platform and, in some cases, opening the door to new product development opportunities.

611 articles with Seattle Genetics, Inc.

A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.

Since Amgen shut down its Bothell, Wash. site in 2014, life science employment growth has increased 13 percent across the state. According to The Seattle Times, companies across the region are in a scaling up process.

Despite having achieved a record net sales of $477 million driven by the success of its powerhouse medication Adcetris in 2018, as well as a 58 percent increase in sales during the fourth quarter in comparison to the previous year, Seattle Genetics stock fell as the results did not meet analysts’...

According to a BioSpace Community Survey, almost 70% of life sciences professionals plan to look for a new job in the next 12 months. Don't delay, accelerate your job search and check out top companies who are looking for quality candidates in 2019!

Dec. 19, 2018 13:00 UTC
BOTHELL, Wash.--( BUSINESS WIRE )--
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management
will present at the 37 th Annual J.P. Morgan Healthcare
Conference on Monday, January 7, 2019 at 2:30 p.m. Pacific Time. Both
the presentation and question and answer session that follows at 3:00
p.m. will be webcast live and available for replay from Seattle
Genetics’ website at www.seattlegeneti

The American Society of Hematology Annual Meeting is always chock full of interesting research and development stories. Here’s a look at some of the highlights of the meeting so far, which is continuing today.

Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from three ongoing clinical trials evaluating the combination of ADCETRIS (brentuximab vedotin) and Opdivo (nivolumab) at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, Calif., December 1-4, 2018.

The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.

Seattle Genetics, Inc. announced today that the company will webcast an investor and analyst event on Monday, December 3, 2018 during the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, Calif.

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced a new approval for ADCETRIS® (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.S. Food and Drug Administration (FDA) for adults with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified.

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SEA-BCMA for patients with relapsed or refractory multiple myeloma (MM).